glp-1 obesity drug news today september 29 2025 Weight-loss drugs such as Ozempic were in the headlines a lot in – and patent protections for these drugs expire in some countries in 2026. In this edition of #PeriodicGraphics in @ The Ozempic conversation everyone needs

Ma cos' esattamente la carnitina

Tendons and ligaments are notoriously slow to regenerate because they have limited blood supplyremember the angiogenesis discussion earlier

Thursdays readout could cast an even longer shadow of doubt over Novos obesity pipeline, particularly after the disappointing Phase II results for its small molecule oral cannabinoid receptor 1 agonist monlunabant, which in September showed modest weight reductions muddied by psychiatric side effects

Researchers should also consider that compounds that increase GH, such as sermorelin, are contraindicated in subjects with a history of oncological conditions

It works through a unique mechanism involving the activation of two different types of receptors in the body: the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor

Dose adjustments